ALX Oncology Holdings Inc (NASDAQ:ALXO) shares are trading higher by 19.3% at $74.69, potentially in sympathy with Trillium Therapeutics which announced an acquisition by Pfizer Monday.
ALX Oncology is a clinical-stage immuno-oncology company. The firm is focused on developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune systems.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ALX Oncology's lead product candidate under development, ALX148, is a next-generation CD47 blocking therapeutic for the treatment of first-line head and neck cancer and second-line gastric/gastroesophageal junction cancer and breast cancer.
ALX Oncology has a 52-week high of $117.45 and a 52-week low of $32.51.